Ever since Huggins and Hodges first demonstrated the efficacy of the technique to treat metastatic prostate cancers in 1941, androgen deprivation therapy (ADT) in the form of castration via orchiectomy or using luteinizing hormone-releasing hormone agonists (LHRH agonists) and luteinizing hormone-releasing hormone antagonists (LHRH antagonists) has been the first line of management for advanced prostate cancers [4]. This evidence concerns the gene GNRH1 and prostate carcinoma.